Join the Omalizumab group to help and get support from people like you.
Omalizumab News
AAAAI: Omalizumab Superior to Placebo for Those With Multiple Food Allergies
MONDAY, Feb. 26, 2024 – Omalizumab treatment for 16 weeks is superior to placebo for increasing the reaction threshold for peanut and other food allergens among persons with multiple food allergies,...
FDA Approves Xolair as First and Only Medicine for Children and Adults With One or More Food Allergies
South San Francisco, CA – February 16, 2024 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved...
Many Primary Care Docs Unaware of Biologic Asthma Meds
TUESDAY, Nov. 21, 2023 – Biologic drugs to treat asthma have been around for two decades, but a surprising number of family doctors still aren’t prescribing them to kids and adults. A new survey f...
FDA Approves Xolair (omalizumab) Prefilled Syringe for Self-Injection Across All Indications
South San Francisco, CA – April 12, 2021 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved the...
Genentech Announces FDA Approval of Xolair (omalizumab) for Adults with Nasal Polyps
South San Francisco, CA – December 1, 2020 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved the...
FDA Approves Genentech’s Xolair (omalizumab) for Allergic Asthma in Children
South San Francisco, CA – July 7, 2016 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved Xolair...
FDA Medwatch Alert: Xolair (omalizumab): Drug Safety Communication - Slightly Elevated Risk of Cardiovascular and Cerebrovascular Serious Adverse Events
ISSUE: An FDA review of safety studies suggests a slightly increased risk of problems involving the heart and blood vessels supplying the brain among patients being treated with the asthma drug...
FDA Approves Xolair (omalizumab) for Chronic Idiopathic Urticaria
South San Francisco, Calif. – March 21, 2014 – Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) approved Xolair (omalizumab) for the...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related condition support groups
Urticaria, Hives, Asthma, Asthma - Maintenance, Nasal Polyps